NewAmsterdam Pharma doses first participant in Phase 2b SPINOZA trial for preclinical Alzheimer’s

NewAmsterdam Pharma announced dosing the first participant in SPINOZA, a Phase 2b trial testing obicetrapib in preclinical Alzheimer’s disease.Key Highlights:Original SEC Filing: NewAmsterdam Pharma Co N.V. [ NAMS ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Co…